The technology, called biventricular
pacing (or cardiac resynchronization therapy, CRT), was federally approved in 2001 to treat heart failure.
With the initiation of the biventricular
pacing both ventricles activate simultaneously, thus LV becomes able to complete the contraction and begin relaxation earlier, which causes an increase in ventricular filling time.
The first non-randomized trials on the clinical effects of CRT demonstrated a significant benefit of patients implanted with biventricular
pacing decrease ventricular arrhythmogenesis?
Barold, the FDA clinical reviewer of the device, said that the agency has requested more safety data from Medtronic, including information on whether the addition of biventricular
pacing interferes with the device's ability to sense ventricular fibrillation; whether inappropriate shocks, which are expected with an ICD, are increased with this device; and whether the ICD interferes with the biventricular
In our case, echocardiography revealed biventricular
dilatation with severely impaired systolic function.
The less than two-thirds response rate to active biventricular
pacing in MIRACLE highlights the need to develop more precise selection criteria for this costly and invasive therapy.
pacemakers seemingly offer the very attractive opportunity to improve cardiac function and at the same time prevent sudden death, which is so common in heart failure patients.
pacemakers, also known as cardiac resynchronization therapy pacemakers (CRT-P)
Kaul, described repeated successful surgical rescues of early and delayed ruptures of ventricular septum, right ventricle and aneurysmal left ventricle following massive biventricular
infarction subsequent to the occlusion of a hyperdominant LAD, albeit in the presence of a normally arising but modestly distributed RCA.11